RSS   Newsletter   Contact   Advertise with us

Akari Therapeutics appoints new members to its board

Share on Twitter Share on LinkedIn
Staff Writer | New York, N.Y., USA | October 17, 2016
Robert WardOctober 17, 2016, New York, N.Y., USA - Akari Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment to its board of directors of Robert Ward.
M. Ward, who has also been appointed chair of the nominating and governance committee, has a diverse and extensive pharmaceutical industry background spanning over 25 years.

Mr. Ward serves as President and Chief Executive Officer and a member of the Board of Radius Health, Inc., a NASDAQ listed biopharmaceutical company, since December 2013.

Prior to leading Radius, Mr. Ward was Vice President for Strategy and External Alliances for AstraZeneca (AZ).

At the annual general meeting of shareholders in June 2016, Donald Williams was elected to Akari’s Board of Directors.

Following his election, he was appointed chair of the audit committee.

Mr. Williams is a 35-year veteran of the public accounting industry. He spent 18 years as a partner at Ernst & Young and the last seven years as a partner at Grant Thornton. Mr. Williams’ career focused on private and public companies in the technology and life sciences sectors.

During the last seven years at Grant Thornton, he served as the National Leader of Grant Thornton’s Life Sciences Practice and the Managing Partner of the San Diego Office.

Akari also announced that Mark Cohen, a director, has stepped down from the Board inorder to serve as outside counsel to Akari on US intellectual property matters, and that David Byrne, who was appointed to the Board of Directors in April 2016, has been appointed to the compensation committee.

Mr. Cohen, who was Chairman of Celsus Therapeutics, Plc which merged in September 2015 with Volution Immuno Therapeutics, SA and then changed its name to Akari Therapeutics, Plc, served as Vice Chairman of the Board, chair of the nominating and governance committee and as a member of the compensation committee.

Mr. Cohen played a significant role in the merger of Celsus and Volution, and was instrumental in the successful integration of the two companies.

Mr. Cohen, who is a Senior Partner and Chair of the Life Science Practice Group at the firm of Pearl Cohen Zedek Latzer Baratz, will, through his firm, be outside counsel to the company on US intellectual property matters.